ジョイクル医薬品の考察と市場予測 - 2032年

当レポートでは、ジョイクル医薬品の主要6市場（米国、ドイツ、フランス、イタリア、スペイン、英国）およびカナダ市場、韓国市場について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症におけるジョイクルの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 ジョイクル市場の評価

• 変形性関節症におけるジョイクルの市場見通し
• 韓国の主要6市場、カナダと分析
  • 主要6市場、カナダ、韓国の変形性関節症向けジョイクルの市場規模
• 市場の分析：国別
  • 米国の変形性関節症向けジョイクルの市場規模
  • ドイツの変形性関節症向けジョイクルの市場規模
  • 英国の変形性関節症向けジョイクルの市場規模
  • カナダの変形性関節症向けジョイクルの市場規模
  • 韓国の変形性関節症向けジョイクルの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: JOYCLU, Clinical Trial Description, 2023
• Table 2: JOYCLU, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: JOYCLU Market Size in the 6MM, Canada and Korea, in USD million (2019-2032)
• Table 6: JOYCLU Market Size in the US, in USD million (2019-2032)
• Table 7: JOYCLU Market Size in Germany, in USD million (2019-2032)
• Table 8: JOYCLU Market Size in France, in USD million (2019-2032)
• Table 9: JOYCLU Market Size in Italy, in USD million (2019-2032)
• Table 10: JOYCLU Market Size in Spain, in USD million (2019-2032)
• Table 11: JOYCLU Market Size in the UK, in USD million (2019-2032)
• Table 12: JOYCLU Market Size in Canada, in USD million (2019-2032)
• Table 13: JOYCLU Market Size in Korea, in USD million (2019-2032)

List of Figures

• Figure 1: JOYCLU Market Size in the 6MM, Canada and Korea, USD million (2019-2032)
• Figure 2: JOYCLU Market Size in the United States, USD million (2019-2032)
• Figure 3: JOYCLU Market Size in Germany, USD million (2019-2032)
• Figure 4: JOYCLU Market Size in France, USD million (2019-2032)
• Figure 5: JOYCLU Market Size in Italy, USD million (2019-2032)
• Figure 6: JOYCLU Market Size in Spain, USD million (2019-2032)
• Figure 7: JOYCLU Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: JOYCLU Market Size in Canada, USD million (2019-2032)
• Figure 9: JOYCLU Market Size in Korea, USD million (2019-2032)

“"JOYCLU Drug Insight and Market Forecast - 2032" report provides comprehensive insights about JOYCLU for osteoarthritis in the six major markets. A detailed picture of the JOYCLU for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the JOYCLU for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JOYCLU market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's own proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. JOYCLU is the first ethical drug indicated for hip joint OA in Japan among the joint function improvement agents. JOYCLU is approved for OA treatment (knee joint and hip joint) and is expected to improve OA symptoms. Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered low. JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's own proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Further, since JOYCLU is administered directly into the joint cavity as an injectable treatment, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is thought to be low. Ono Pharmaceutical and Seikagaku aim to contribute to the improvement of quality of life (QOL) in patients by providing a new treatment option for OA (knee joint and hip joint)

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the JOYCLU description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on JOYCLU regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JOYCLU research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around JOYCLU.
• The report contains forecasted sales of JOYCLU for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for JOYCLU in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JOYCLU Analytical Perspective by DelveInsight

• In-depth JOYCLU Market Assessment

This report provides a detailed market assessment of JOYCLU for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

• JOYCLU Clinical Assessment

The report provides the clinical trials information of JOYCLU for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JOYCLU dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to JOYCLU and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JOYCLU in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of JOYCLU from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JOYCLU in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of JOYCLU?
• What is the clinical trial status of the study related to JOYCLU in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JOYCLU development?
• What are the key designations that have been granted to JOYCLU for osteoarthritis?
• What is the forecasted market scenario of JOYCLU for osteoarthritis?
• What are the forecasted sales of JOYCLU in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to JOYCLU for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. JOYCLU Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. JOYCLU Market Assessment

• 5.1. Market Outlook of JOYCLU in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of JOYCLU in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of JOYCLU in the United States for Osteoarthritis
  • 5.3.2. Market Size of JOYCLU in Germany for Osteoarthritis
  • 5.3.3. Market Size of JOYCLU in France for Osteoarthritis
  • 5.3.4. Market Size of JOYCLU in Italy for Osteoarthritis
  • 5.3.5. Market Size of JOYCLU in Spain for Osteoarthritis
  • 5.3.6. Market Size of JOYCLU in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of JOYCLU in Canada for Osteoarthritis
  • 5.3.8. Market Size of JOYCLU in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options